quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 26, 2026

1 AI Stock I Wouldn't Touch, and 1 I Absolutely Love

View original at nasdaq.com
“In Q4, the company reported a generally accepted accounting principles (GAAP) net loss of $12.1 million.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Stock Advisor's total average return is 900% compared to 184% for the S&P 500

    60% confidence
  • Apple is well-positioned to capture a multiyear wave of high-margin device sales while also tapping new software and services opportunities in an AI era

    60% confidence
  • New annual contract value bookings grew by nearly 50% year over year

    60% confidence
  • Apple wasn't one of the 10 best stocks for investors to buy now

    60% confidence
  • Apple will likely be a major AI beneficiary without having to invest the same extraordinary sums that software and cloud providers do

    60% confidence
  • Cloudflare's inability to turn a true profit makes its sky-high valuation too risky

    60% confidence
  • Apple's stock has a bullish outlook over the next five years

    60% confidence
  • Apple gives investors a front-row seat to the consumer AI revolution while providing the safety of a highly profitable, cash-generating business

    60% confidence

Data points we hold from this source

Apple Podcasts · price to earnings ratio32 ratio
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
1 AI Stock I Wouldn't Touch, and 1 I Absolutely Love — Source | Via News | pt.VIA.NEWS